Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 12, Issue 1, Pages 27-30Publisher
EXPERT REVIEWS
DOI: 10.1586/ERN.11.171
Keywords
Alzheimer's disease; atorvastatin; cholesterol; clinical trials; cognitive decline; simvastatin; statins
Categories
Funding
- Pfizer
- Eisai
- Lilly
- BMS
- Baxter
- Bayer
- GE
- Genentech
- Avid
- NIH-NIA [P30 AG019610]
- Amerisciences
- Wiley
- ISOA
Ask authors/readers for more resources
The link between cholesterol and Alzheimer's disease (AD) has been explored for almost two decades. The link stems from the observation that atherosclerotic heart disease increases the risk for AD and that people expiring from coronary artery disease had AD changes in their brains. Cholesterol is a cofactor of amyloid deposition, with substantial evidence showing that high cholesterol diets in animal models can accelerate amyloidogenesis. This link led investigators to posit the use of cholesterol-lowering agents as treatments for AD and cognitive decline. Indeed, the epidemiological data suggest that cholesterol-lowering agents may reduce the risk of developing AD. Early pilot studies suggested that statins may be useful as treatments for AD because of a reduction in the rates of decline. Recent reports of simvastatin and atorvastatin assessed in large randomized, double-blind, placebo-controlled multicenter trials have not confirmed a clinically demonstrable cognitive benefit for statins in the treatment of AD. This article will discuss the results of one of these trials and explore the reasons behind why the multicenter trials may not have been positive and the growing disparity between preclinical/epidemiological benefit and a lack of clinical efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available